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Abstract
Background
Previous studies of radiological damage in rheumatoid arthritis (RA) have used candidate-
gene approaches, or evaluated single genome-wide association studies (GWAS). We
undertook the first meta-analysis of GWAS of RA radiological damage to: (1) identify novel
genetic loci for this trait; and (2) test previously validated variants.
Methods
Seven GWAS (2,775 RA cases, of a range of ancestries) were combined in a meta-analysis.
Radiological damage was assessed using modified Larsen scores, Sharp van Der Heijde
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scores, and erosive status. Single nucleotide polymophsim (SNP) associations with radio-
logical damage were tested at a single time-point using regression models. Primary analy-
ses included age and disease duration as covariates. Secondary analyses also included
rheumatoid factor (RF). Meta-analyses were undertaken in trans-ethnic and European-only
cases.
Results
In the trans-ethnic primary meta-analysis, one SNP (rs112112734) in close proximity to
HLA-DRB1, and strong linkage disequilibrium with the shared-epitope, attained genome-
wide significance (P = 4.2x10-8). In the secondary analysis (adjusting for RF) the association
was less significant (P = 1.7x10-6). In both trans-ethnic primary and secondary meta-analy-
ses 14 regions contained SNPs with associations reaching P<5x10-6; in the European pri-
mary and secondary analyses 13 and 10 regions contained SNPs reaching P<5x10-6,
respectively. Of the previously validated SNPs for radiological progression, only rs660895
(tagging HLA-DRB1*04:01) attained significance (P = 1.6x10-5) and had a consistent direc-
tion of effect across GWAS.
Conclusions
Our meta-analysis confirms the known association between the HLA-DRB1 shared epitope
and RA radiological damage. The lack of replication of previously validated non-HLA mark-
ers highlights a requirement for further research to deliver clinically-useful prognostic
genetic markers.
Background
Rheumatoid arthritis (RA) is a heterogeneous disease, exhibiting a variable course between
patients. Prospectively identifying patients likely to develop severe phenotypes could allow
early intensive therapy to be focussed on poor prognosis cases. This approach should optimise
clinical and cost-effectiveness, but requires accurate prognostic markers.
Radiological damage is one measure of RA severity. It is moderately heritable (heritability
from common variants estimated at 45%-58%) suggesting genetic markers could represent
useful prognostic biomarkers [1]. The strongest genetic association with RA radiological pro-
gression is the shared epitope (SE), which represents consensus amino acid sequences
(QRRAA, RRRAA and QKRAA) spanning positions 70–74 in the HLA-DRβ1 molecule,
encoded by various HLA-DRB1 SE alleles [2]. The SE has been demonstrated to associate with
greater radiological damage in a broad range of RA populations [3,4], although as it associates
with the presence of rheumatoid factor (RF) and antibodies to citrullinated peptide antigens
(ACPA) [5], both of which independently associate with radiological damage [6], its impact
may be mediated by autoantibody status. Van Steenbergen et al previously identified a further
16 “validated” non-HLA variants (in 11 genes) for RA radiological progression [7]. In the Lei-
den Early Arthritis Cohort (EAC) these variants, in combination with the SE, explained up to
18% of the variance in radiological progression, although as this cohort was used to identify
many of the variants, this finding requires replication.
The gold standard to identify genetic associations with a phenotype or trait is to perform a
meta-analysis of all available genome-wide association studies (GWAS). To date, this has not
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been performed for RA radiological damage. Five individual GWAS have identified four non-
HLA variants − rs7607479 in SPAG16, rs451066 in RAD51L1-ZFP36L1, rs11908352 in
SLC12A5, and rs2833522 in HUNK/SCAF4 –associating with RA radiological damage that
passed multiple testing correction thresholds, and replicated externally [8–11]. These studies
were limited by modest sample sizes, with the largest containing 646 patients. Combining
GWAS in a meta-analysis should increase statistical power to detect novel loci.
To this end, we have carried out the largest GWAS of RA radiological damage, by peform-
ing and then combining seven independent GWAS (totalling 2,775 patients). We aimed to
identify novel genetic loci for radiological damage. We also tested previously validated single
nucleotide polymorphisms (SNPs) for their association with radiological damage.
Methods
Patients
GWAS were undertaken in: (1) Combination Anti-Rheumatic Drugs in Early RA (CAR-
DERA) Genetics Cohort; (2) Yorkshire Early Arthritis Registry (YEAR); (3) Brigham and
Women’s Hospital RA Sequential Study (BRASS); (4) Leiden Early Arthritis Clinic (EAC); (5)
North American RA Consortium (NARAC); (6) GENetics of RA in individuals of African
ancestry (GENRA) study; (7) South London RA Study (SLRAS). These cohorts have been
described in detail previously [12–17]. An overview is provided in Table 1 (with further details
in S1 Table).
Radiological measures
Hand and feet X-rays were scored using either the Scott modification of the Larsen method
(scoring 0–200 for joint space narrowing and erosive damage [18]), Sharp van Der Heidje
Scores (SvHS; scoring 0–448 for joint space narrowing and erosive damage [19]) or erosions
(present/absent). Larsen and SvHS are highly correlated; both evaluate erosions [20].
Table 1. Cohort characteristics.
Characteristic CARDERA (n = 505)
[12]
YEAR
(n = 403)
[13]
BRASS
(n = 422) [14]
SLRAS
(n = 284) [17]
GENRA (n = 196)
[16]
Leiden EAC (n = 595)
[13]
NARAC (n = 370)
[15]
Ancestry European European European Mixed African European European
Recruitment Site England England North
America
England England Netherlands North America
Female, n (%) 345 (68.7) 278 (69.0) 341 (80.8) 227 (80.0) 164 (83.7) 400 (67.2) 272 (73.5)
Mean Age 54.5 (12.6) 60.3 (13.6) 58.9 (13.7) 60.9 (12.8) 56.2 (14.8) 57.1 (15.6) 40.8 (11.9)
Mean Disease Duration in
Yrs (SD)
2.28 (0.41) 2.21 (1.17) 17.0 (12.7) 15.5 (11.6) 9.3 (10.2) 4.9 (2.2) 14.1 (10.6)
RF-Positive, n (%) 340 (67.3) 279 (69.2) 422 (100) 210 (75.5) 153 (78.1) 340 (57.4) Unavailable
ACPA-Positive, n (%) 342 (67.7) 195 (65.9) 422 (100) Unavailable 152 (77.6) 308 (52.8) 370 (100)
X-ray Scoring Larsen SvHS SvHS Larsen Erosions SvHS SvHSa
Follow-Up Duration 2 years 2 years 9 years Cross-
sectional
Cross-sectional 7 years Cross-sectional
Median X-ray Score (IQR)b 13 (3–25) 0 (0–5) 25 (5–64) 47 (25–77) Unavailable 18 (7–37) 21 (6–56)
Erosive, n (%) Unavailable 100 (24.8) Unavailable Unavailable 78 (39.8) 570 (95.8) 319 (86.0)
a = in NARAC SvHS were available for hand X-rays only
b = X-ray score at 2 years of follow-up in CARDERA/YEAR, 6 years of follow-up in Leiden EAC, baseline in BRASS, and at a single time-point in SLRAS/GENRA/
NARAC; disease duration is at the time of the X-ray score tested for its association with genetic variants.
https://doi.org/10.1371/journal.pone.0223246.t001
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Genotyping, quality control and imputation
CARDERA was genotyped on the Immunochip, YEAR on the ImmunoChip and HumanOm-
niExpressExome Beadchip, BRASS on the Affymetrix 6.0, Leiden EAC on the Illumina iScan,
GENRA on the Illumina MEGA array, NARAC on the Illumina Beadchip (HumanHap 550k),
and SLRAS on the Illumina HumanOmniExpress. Prior to imputation all cohorts excluded
SNPs with high levels of missingness, low minor allele frequency (MAF), and deviations from
Hardy-weinberg equilibrium (HWE). Individuals were removed that did not segregate with
reference populations, had high-levels of missingness, or whose phenotypic sex mismatched
with sex inferred from genotype data. Genotype phasing and imputation were performed
using SHAPEIT and IMPUTE2, respectively. Data were imputed to the 1,000 Genomes Phase
3 Panel, including all samples regardless of ancestry. Post-imputation markers with INFO
scores<0.7 or MAF <0.05 were removed (the latter was undertaken as we had limited power
to detect associations with low frequency variants). Genotypes were analysed as expected allele
“dosages” in all analyses. Genotypes were converted to be reported on the forward strand. The
number of variants available post-QC comprised: CARDERA: 3,181,676; YEAR: 6,209,766;
Leiden EAC: 674,614; BRASS: 6,059,126; GENRA: 5,662,513; NARAC: 5,373,610; SLRAS:
5,715,821.”
Statistical analysis
X-ray time-point. As RA X-ray progression can be non-linear [21], and several cohorts
had cross-sectional X-ray scores, we tested SNP associations with radiological damage at a sin-
gle time-point. In the repeated measures early RA cohorts (CARDERA, YEAR, and Leiden
EAC) associations with end-point X-ray scores were tested (when radiological damage was
greatest). In the repeated measures established RA cohort (BRASS) associations with baseline
X-ray scores were tested (when sample size was greatest).
Statistical models. Log-transformed Larsen/SvHS, or binary erosive status were used as
response variables. Outcomes were regressed on imputed genotype dosages assuming an addi-
tive genetic model using linear (in CARDERA, Leiden EAC, BRASS, SLRAS, and NARAC),
negative binomial (in YEAR, due to over-dispersion) or logistic (in GENRA) regression
models.
The same modelling covariates were included to provide consistency. Sex, age, disease
duration, rheumatoid factor (RF) and (where available) treatment were tested for associations
with X-ray scores in each cohort to determine the best predictors across studies. Only age and
disease duration were associated with radiological scores in every cohort, and these were
included as covariates. Ancestry-informative principal components (PCs) were included to
account for population stratification. These were calculated using EIGENSTRAT. Different
numbers were used in each study, with a minimum of 2 used [22].
Two analyses were undertaken: a primary analysis using these covariates, and a secondary
analysis, including RF as an additional covariate to account for genetic variants exerting their
effects through RF formation (which associates with both the SE and X-ray damage).
Meta-analysis. SNP association results from GWAS were combined using a Z-score
weighted approach in METAL [23]. METAL performs a meta-analysis using information on
P-values, effect directions, and the number of cases evaluated at each SNP. This method was
used because other meta-analysis methods, such as the inverse variance-weighted average
method [24], require effect size data at each marker, and as our various GWAS utlised different
statistical models and X-ray scoring systems, their beta-values were non-comparable.
We assessed QQ-plots and genomic inflation factors to confirm that genome-wide statistics
had the expected distributions. Genomic control correction was used to adjust for any residual
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inflation of test statistics. In the overall meta-analysis of all SNPs, we only analysed SNPs that
had been genotyped or imputed in at least half of all individuals in the total sample.
Two meta-analyses were performed: (1) a trans-ethnic meta-analysis (maximising sample
size); (2) a European ancestry meta-analysis (reducing heterogeneity across populations).
Associations with previously validated SNPs. Van Steenbergen et al reported 17 vali-
dated variants for radiological progression. These comprised variants in the following 12 loci:
SPAG16, IL-15, C5orf30, HLA-DRB1, OPG, DKK-1, IL2RA, RAD51L1/ZFP36L1, GRZB, IL-4R,
MMP-9, and CD40. They defined “validated” as being a SNP studied in several cohorts, with
the association independently replicated or found significant in a meta-analysis of all pub-
lished data [7]. We tested their association with radiological damage in our meta-analysis. We
included all available SNPs, regardless of if they were present in less than half of all individuals.
We used the HLA-DRB1�04:01 tagging SNP (rs660895) identified in the Eyre et al RA suscepti-
bility meta-analysis [25] to represent the SE, as this is the commonest SE-encoding allele in RA
cases [2].
Significance thresholds. For the testing of previously validated SNPs we used a Bonfer-
roni corrected P-value of 0.004167 (12 loci tested). For the genome-wide analyses we used the
standard P-value threshold of<5x10-8 for genome-wide significance, and<5x10-6 for “sugges-
tive” significance. In the genome-wide trans-ethnic analysis, based on sampling from a Chi-
squared distribution with NCP ¼ Nq
2
1  q2, where q is trait variance and N is sample size, we had
80% power to detect a variant explaining 1.4% of the variance of X-ray damage at P<5x10-8
[26]. We made assumptions to enable us to perform a power calculation for this heterogeneous
dataset. As most datasets used the quantitative Larsen scale, we simulated chi-squared statistics
with an NCP given by N�qtl_variance/(1-qtl_variance) and calculated power based on the
number of observations reaching genome-wide significance, using the principles reported by
Yang et al [26]. We assumed we had 80% study power for qtl_variance values which produced
genome-wide significant values for 80% of simulations.
Ethics approval and consent to participate
Ethical approval was granted for each of the genetic studies as follows: CARDERA genetics
cohort was approved by the National Research Ethics Service Committee East of England—
Essex (reference: 11/EE/0544); YEAR by the Multi-Centre Research Ethics Committee
(MREC) (reference 99/3/48); Leiden EAC by the Medical Ethics Committee Leiden University
Medical Center; BRASS by the Institutional Review Board of Brigham and Women’s Hospital,
Partners Health Care, Boston, MA; GENRA by the National Research Ethics Service Commit-
tee London—Dulwich (reference: 11/LO/1244); NARAC by the Via Christi Institutional
Review Board and North Shore-LIJ Health System Institutional Review Board; SLRAS by the
Guy’s Hospital Local Research Committee (reference 99/11/06) and Lewisham Hospital Local
Research Committee (reference 01/05/02). Informed consent was provided by all participating
patients.
Availability of data and materials
Individual-level genotype and phenotype data from each of the separate GWAS are not publi-
cally available, as the centres from which patients were recruited are reported in the primary
publications outlining the individual genetic datasets, leading to the potential for patient confi-
dentiality to be affected. Summary statistics will be made available through the NHGRI-EBI
GWAS Catalog (https://www.ebi.ac.uk/gwas/downloads/summary-statistics). Further data
requests can be made to the following non-author contacts: Ms Isabel Sinha (isabel.sinha@kcl.
ac.uk) for CARDERA, GENRA, and SLRAS; Dr James Robinson (J.I.Robinson@leeds.ac.uk)
Genetics of radiological damage in rheumatoid arthritis
PLOS ONE | https://doi.org/10.1371/journal.pone.0223246 October 9, 2019 5 / 12
for YEAR; Vivi Feathers (vfeathers@bwh.harvard.edu) for BRASS; Dr Annette Lee (Anlee@-
northwell.edu) for NARAC; and Dr E Niemantsverdriet (E.Niemantsverdriet@lumc.nl) for the
Leiden EAC.
Results
Cohort characteristics
Cohort characteristics are presented in Table 1. The majority of cases were female (67.2–
80.8%), and seropositive (57.4–100% RF-positive; 52.8–100% ACPA-positive). The mean age
in all cohorts was between 54.5 and 60.9 years, except NARAC, which had a mean age of 40.8
years. As expected, the cohorts containing established RA patients had higher rates of radiolog-
ical damage than those evaluating early RA patients. The total number of patients included in
the trans-ethnic and European meta-analyses comprised 2,775 and 2,527 cases, respectively.
The total number of SNPs assessed in the trans-ethnic meta-analysis was 4,802,696, and in the
European meta-analysis was 2,723,488.
Trans-ethnic meta-analysis
In the primary analysis (age and disease duration as covariates), one SNP (rs112112734, on
chromosome 6, in close proximity to HLA-DRB5, HLA-DRB6 and HLA-DRB1) attained
genome-wide significance (P = 4.2x10-8, regional association plot in Fig 1). The same direction
of effect was observed in the 6 GWAS in which this marker was available (it was absent in the
Leiden EAC). This SNP is in strong linkage disequilibrium (LD) with the HLA-DRB1 SE (R2 =
0.93 with the lead HLA-DRB1 SNP, rs9268839, from the Okada et al RA susceptibility meta-
analysis [27]). Fourteen regions contained SNPs with associations reaching P<5x10-6 (S2
Table).
In the secondary analysis (age, disease duration and RF as covariates), no SNPs attained
genome-wide significance. Fourteen regions contained SNPs with associations reaching
P<5x10-6, one of which was rs112112734 (P = 1.7x10-6) (S3 Table). Plots of–log10(P-value) by
genomic position for the trans-ethnic and European analyses are provided in Fig 2, and QQ
plots in S1 Fig.
European meta-analysis
In the primary analysis, thirteen regions contained SNPs reaching P<5x10-6 (S2 Table), with
the most significant SNP being rs112112734 (P = 8.6x10-8).
In the secondary analysis, ten regions contained SNPs with associations reaching P<5x10-6
(S3 Table). rs112112734 was not amongst these.
Previously validated SNPs
Two SNPs associated with radiological damage in our European meta-analysis (Table 2).
These comprised: (1) rs660895 (tagging HLA-DRB1�04:01; P = 1.6x10-5) which had the same
direction of effect across all 6 GWAS (the G allele, indicating an �04:01 copy, associating with
increased damage), and (2) rs7607479 (in SPAG16), which was available in four GWAS, two of
which had increased and two reduced radiological damage associated with the T allele. In the
trans-ethnic meta-analysis, only rs660895 was significant (P = 7.0x10-5) with the same direc-
tion of effect observed in all but one GWAS. Only 2 SNPs in the trans-ethnic meta-analysis,
and 4 SNPs in the European meta-analysis had a shared direction of effect across all available
GWAS.
Genetics of radiological damage in rheumatoid arthritis
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Discussion
Our study has three key findings. Firstly, it confirms the known association between this trait
and the HLA-region, with one SNP in this region (rs112112734, in high LD with the
HLA-DRB1 SE) attaining genome-wide significance. Secondly, it demonstrates the challenges
in replicating genetic variants for traits across GWAS. Of the 17 previously validated SNPs,
only the HLA-DRB1�04:01 tagging SNP had a significant association and consistent direction
of effect across GWAS. Thirdly, it highlights the difficulties in performing meta-analysis of
GWAS of continuous disease outcomes like RA radiological damage, which involves combin-
ing summary statistics from highly heterogeneous patient cohorts.
The association between the SE and radiological damage in RA is well established [3]. As
the SE associates with RF and ACPA, which themselves are linked with radiological damage,
Fig 1. Regional association plot for region surrounding rs112112734 showing evidence of significance at P<5x10-8 in the primary trans-ethnic
meta-analysis.
https://doi.org/10.1371/journal.pone.0223246.g001
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we undertook a secondary analysis including RF as a covariate (ACPA was not used, as ACPA
status was unavailable in SLRAS, and two cohorts only included ACPA-positive cases). The
association observed at chromosome 6 was less significant in this secondary analysis, and
rs112112734 no longer reached genome-wide significance. This suggests the observed
Fig 2. Manhattan plots for radiological damage. Panel A = trans-ethnic primary analysis; Panel B = European
primary analysis; Panel C = trans-ethnic secondary analysis; Panel D = European secondary analysis; primary analysis
includes age, disease duration and genotypes as explanatory variables; secondary analysis also includes RF as an
explanatory variable.
https://doi.org/10.1371/journal.pone.0223246.g002
Table 2. Previously validated genetic variants for radiological progression reported by Van Steenbergen et al [7], and their association with radiological damage.
Trans-ethnic European
Variant Gene Chr A1/A2 A1 Freq. Cohort Direction P A1 Freq. Cohort Direction P
rs7607479 SPAG16 2 T/C 0.53 -+?-?++ 4.4x10-3 0.55 -+?-?+ 4.0x10-3
rs4371699 IL-15 4 A/C 0.33 ++?+?++ 0.0869 0.38 ++?+?+ 0.0445
rs6821171 IL-15 4 T/G 0.66 +–+?++ 0.7913 0.65 +–+?+ 0.5901
rs7665842 IL-15 4 T/C 0.65 -++-?-+ 0.6102 0.63 -++-?- 0.4719
rs7667746 IL-15 4 T/C 0.60 -+?-?-+ 0.3014 0.55 -+?-?- 0.1528
rs26232 C5orf30 5 T/C 0.45 –+–++ 0.5763 0.46 –+–+ 0.4193
rs660895 HLA-DRB1�04:01 6 A/G 0.56 –+– 7.0x10-5 0.54 ———— 1.6x10-5
rs1485305 OPG 8 A/T 0.50 +++-?+- 0.7832 0.53 +++-?+ 0.5594
rs1528873 DKK-1 10 A/C 0.55 ++?-?– 0.4979 0.53 ++?-?- 0.6317
rs1896367 DKK-1 10 T/C 0.44 ++?+?+? 0.1337 0.44 ++?+?+ 0.1304
rs1896368 DKK-1 10 T/C 0.47 ++?+?+- 0.2077 0.50 ++?+?+ 0.1749
rs2104286 IL2RA 10 T/C 0.56 -+-++-? 0.8596 0.55 -+-++- 0.9270
rs451066 RAD51L1, ZFP36L1 14 A/G 0.41 -+-++-+ 0.6024 0.44 -+-++- 0.6415
rs8192916 GRZB 14 A/G 0.43 +-?+??- 0.7444 0.39 +-?+?? 0.7408
rs1119132 IL-4R 16 A/G 0.38 –+-+++ 0.1923 0.41 –++++ 0.1912
rs11908352 MMP-9 20 A/C 0.41 ++–+-+ 0.2055 0.43 ++–+- 0.2169
rs4810485 CD40 20 T/G 0.41 +–+-+- 0.4666 0.44 +–+-+ 0.4924
Cohort direction indicates the direction of the SNP A1 allele effect on X-ray damage across the cohorts (+ means it is associated with increased damage,—means it is
associated with decreased damage, and ? means the SNP was unavailable in the cohort). Cohort order comprises YEAR, BRASS, CARDERA, SLRAS, Leiden, NARAC,
GENRA in the trans-ethnic analysis and YEAR, BRASS, CARDERA, SLRAS, Leiden, and NARAC in the European analysis); results in the table are from the primary
analysis (including age and gender as covariates). Note that (a) Stouffer’s meta-analysis method does not permit effect sizes to be calculated, and (b) the effect direction
for the SLRAS cohort differs at two markers (rs660895 and rs1119132) because it is a mixed-ethnicity cohort and different individuals were included in the trans-ethnic
and European analyses in this GWAS.
https://doi.org/10.1371/journal.pone.0223246.t002
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association between the HLA-region and X-ray damage in our meta-analysis may be, at least
in part, mediated by autoantibody production. More recently, Viatte et al reported that amino
acid polymorphisms at position 11 in HLA-DRβ1 also associate with erosions, independently
of the shared epitope [28]; owing to an absence of imputed amino acid polymorphism data,
and the fact that this amino acid polymorphism is not “tagged” by a single SNP, we were
unable to evaluate this association within our meta-analysis. Future research should focus on
fine mapping of the HLA locus to provide a more comprehensive understanding of the associ-
ation between HLA alleles and X-ray damage.
Our failure to replicate associations for previously validated non-HLA markers is disap-
pointing. There are several potential explanations for this. Firstly, the validated variants
reported by Van Steenbergen et al were for radiological progression, and we tested their associ-
ation with radiological damage (although only radiological “progressors” will accrue damage).
Secondly, several of these variants were identified in ACPA-positive cases only, and our
cohorts included cases with a range of frequencies of ACPA. Thirdly, not all SNPs were avail-
able in all cohorts, although only one SNP (rs8192916 in GRZB) had a sample size of<1,000
cases. Irrespective of the explanation, current data on seven GWAS strengthen the notion that
these variants lack clinical utility at identifying severe phenotypes [7].
The strengths of our study are that it represents the largest analysis of genetic predictors of
RA radiological damage, includes individuals from a range of ethnicities (increasing the gener-
alisability of its results), and is the first meta-analysis of an RA prognostic trait. Its weaknesses
are the marked heterogeneity of the included GWAS (which varied in their disease durations,
X-ray scoring systems used, and statistical models), and its modest sample size, limiting our
ability to detect variants of a small effect size. As our meta-analysis replicated the genetic locus
with the largest effect size for radiological damage (the HLA region), we consider that our
modest sample size is the most likely reason we did not identify non-HLA associations attain-
ing genome-wide significance. An alternative explanation is that the trait of radiological dam-
age has low heritability. Due to a modest sample size, and clinical heterogeneity, we could not
determine heritability in our GWAS meta-analysis with confidence, although previous
research has reported RA radiological damage to be moderately heritable (estimated heritabil-
ity rate of 45–58%) [1].
Conclusions
In conclusion, our meta-analysis replicates the association between the HLA-region and radio-
logical damage in RA. It demonstrates the complexities of undertaking meta-analysis of
GWAS of RA characteristics. For these to be more precisely defined, a collaborative interna-
tional approach is required, standardising the collection of phenotypic data in genotyped
patients, creating large homogeneous cohorts that are suitable for meta-analysis.
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S1 Fig. QQ plots for meta-analyses. A = primary trans-ethnic meta-analysis (inflation factor
1.00); B = primary European meta-analysis (inflation factor 1.01); C = secondary trans-ethnic
meta-analysis (inflation factor 1.00); D = secondary European meta-analysis (inflation factor
1.00).
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